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Summary
Evidence for the effectiveness of exercise to improve
physical functioning, body composition, fatigue and quality
of life in cancer patients is promising and, in general, exer-
cise is safe and feasible throughout the course of cancer
care.
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Epidemiology of cancer
A growing and aging population, along with improved
cancer survival rates, are both contributing to increasing
cancer prevalence. Today approximately 300,000 cancer
patients are living in Switzerland, amounting to double the
number of 25 years ago. More than half of all new can-
cer cases are caused by four cancer types: breast (women),
prostrate (men), lung and colorectal cancer (both sexes).
After cardiovascular disease (CVD), cancer is the second
leading cause of death in Switzerland, and the leading
cause of death in the age group of 45 to 84 years in both
women and men [1].
Shared risk factors of cancer and cardiovascu-
lar diseases
Although commonly thought of as two separate disease
entities, CVD and cancer possess various similarities and
possible interactions, including a number of similar risk
factors (table 1). Emerging evidence suggests a shared bi-
ology [2]. Moreover, patients who develop cancer are at
risk for a sedentary lifestyle due to cancer-related exercise
intolerance and suboptimal CVD prevention. The addition
of cardiotoxic radio- and/or chemotherapies contribute to
an even higher CVD risk (fig. 1). Particularly for breast
cancer, this has been acknowledged in a recent scientific
statement of the American Heart Association [3]. In long-
term cancer survivors, CVD has become a leading cause of
death, beside cancer recurrences and other cancers [4].
Cardiovascular complications of cancer thera-
py
Different chemotherapeutic agents, alone or in combina-
tion with radiotherapy, may lead to the development of
CVD (myocardial dysfunction, heart failure, coronary
artery disease, valvular heart disease, arrhythmias, arterial
hypertension, thromboembolic disease, peripheral vascular
disease or stroke) [5]. As an example, anthracycline regi-
mens are widely used in protocols for breast cancer, sar-
coma, lymphoma and paediatric leukaemia. They cause
dose-dependent and progressive cardiac damage, clinically
manifest as decreased left ventricular function, which in
severe cases leads to heart failure and ventricular arrhyth-
mias. The incidence of heart failure increases dose- and
compound-dependent, for example with doxorubicin from
3–5% (400 mg/m2) to 18–48% (700 mg/m2) [5].
Exercise intolerance in cancer patients
The aetiology of exercise intolerance in cancer patients
is multifactorial. Patient-specific limitations, such as age
and comorbidities, interact with disease-specific limita-
tions, such as type of surgery, and chemo-, radio-, or hor-
mone therapies. All may affect oxygen uptake, transport
Table 1: Modifiable cardiovascular health and risk factors with their es-
timated risk for the four most common cancers.
Breast Prostate Lung Colorectal
Physical activity ▼ ▼▼
(colon)
Unhealthy diet ▲ ▲▲
Obesity ▲▲ ▲ (w)
▲▲▲(m)
Diabetes ▲▲ ▲▲
Hypertension ▲ ▲
Tobacco smoking ▲ ▲▲ ▲▲▲
w = women; m = men. Hazard ratios (HR): ▼▼ HR 0.6–0.79, ▼ HR
0.80–0.99, ▲ HR 1.01–1.19, ▲▲ HR 1.20–1.39, ▲▲▲ HR ≥1.40,
adapted from [2, 3].
Figure 1: Shared risk factors and the development of cardiovascu-
lar diseases in cancer patients.
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and utilisation, leading to or aggravating muscular decon-
ditioning [6]. Beside this biological view of exercise in-
tolerance, psychosocial aspects also have to be considered.
The ability to exercise may be impaired because of cancer-
related pain or fatigue. Symptoms of anxiety or depression
may curb or abolish the desire and motivation to exercise.
In addition, lack of time, insufficient social support, a neg-
ative attitude towards exercise and the lack of perceived
benefits from exercise are other barriers towards participa-
tion in regular exercise [7]. Depending on the degree and
duration of inactivity, exercise intolerance may develop,
and a vicious circle of physical deconditioning, fatigue and
inability to exercise may develop, all-in-all negatively af-
fecting quality of life and CVD risk. In analogy to heart
failure, exercise intolerance in cancer patients can be suc-
cessfully tackled by the application of exercise training.
There is still a prevailing clinical mind-set that the devel-
opment of symptoms such as breathlessness and muscular
fatigue indicates that exercise may be adverse to the pa-
tient’s physical condition. Instead, we need to consider that
such symptoms are needed for the signalling between the
periphery and central haemodynamic performance and that
regular physical activity will ultimately lead to favourable
changes in symptoms and functional capacity [8].
Exercise as important adjuvant therapy at all
stages of the cancer care pathway
Observational studies, interventional trials, and meta-
analyses support the view that exercise is an important ad-
junct therapy from pre-treatment to the survivorship stage
(health promotion) or palliative care (quality of life).
Specifically, there is preliminary or promising evidence
that cancer patients involved in higher levels of exercise
have a lower relative risk of cancer mortality, a lower rel-
ative risk of cancer recurrence, and experience fewer and/
or less severe treatment-related adverse effects (table 2) [9,
10].
Table 2: Evidence for the impact of exercise on different outcomes at
different cancer stages.
Breast Prostate Lung Colorectal
Exercise during cancer treatment
Physical function ●● ● ● ●
Fatigue ●● ●/●● ●● ●●
Quality of life ● ● ● ●
Exercise after cancer treatment
Physical function ●/●● ●● ●● ●●
Body composition ● ● ● ●
Fatigue ●/●● ●● ●● ●●
Quality of life ● ● ● ●
Cancer recurrence ● ● ●
Survival ● ● ● ●
Exercise during palliative care
Physical function ● ● ● ●
Body composition ● ● ● ●
Fatigue ● ● ● ●
Quality of life ● ● ● ●
Level of evidence: ● Preliminary – low quality of evidence with consid-
erable uncertainty over the effects demonstrated. ●● Promising – mod-
erate quality body of evidence with some uncertainty over the effects
demonstrated. Adapted from [9].
Modulation of cardiotoxicity by aerobic exer-
cise
The evidence for the effectiveness of exercise to improve
physical functioning, body composition, fatigue and quali-
ty of life in cancer patients is promising, but the evidence
for the efficacy of exercise to prevent or mitigate car-
diovascular toxicity is limited [11]. However, for selected
compounds such as anthracyclines, the underlying mecha-
nisms of cardiotoxicity and the potential of aerobic exer-
cise for prevention and treatment have been studied in an-
imals. Anthracycline-induced oxidative injury accelerates
cardiac myofilament apoptosis, suppresses protein synthe-
sis, leads to ultrastructural changes and impairs mitochon-
drial energy metabolism. These alterations ultimately lead
to myocardial dysfunction and heart failure. Aerobic ex-
ercise interventions may modulate anthracycline-induced
cardiotoxicity by mitigating oxidative stress, apoptosis and
ultrastructural changes, and improving protein synthesis
and mitochondrial energy metabolism [12]. More recently,
studies in humans have been instigated to assess the trans-
ferability of the positive results from animal studies. A
conceptual research framework has been proposed to fa-
cilitate personalised risk assessment and the development
of targeted exercise prescriptions to optimally prevent or
manage cardiovascular toxicity after a cancer diagnosis
[11]. In 2019, the Inselspital Bern launched a study in
breast cancer patients funded by the Swiss Cancer League
to test the hypothesis that anthracycline-mediated car-
diotoxicity can be alleviated with a personalised exercise
training programme (Cancer Adverse effects PReventIon
with Care & Exercise: the CAPRICE study,
NCT03850171).
Exercise recommendations for cancer patients
In 2009, the American College for Sports Medicine (AC-
SM) published a consensus statement on exercise for can-
cer patients [13]. These guidelines were developed against
the backdrop of existing recommendations for exercise
from the ACSM and the American Heart Association, and
the 2008 US Department of Health and Human Services
(US DHHS) Physical Activity Guidelines for Americans.
The latter were updated recently [14]. All of these guide-
lines are similar, with minor variations. The recent US
DHHS guidelines indicate that, when individuals with
chronic conditions such as cancer are unable to meet the
stated recommendation because of their poor health status,
they “should be as physically active as their abilities and
conditions allow.” An explicit recommendation was made
to “avoid inactivity”, and it was clearly stated that “some
physical activity is better than none.” The key US DHHS
guideline for aerobic activity focused on an overall volume
of weekly activity of 150 to 300 min of moderate-intensity
exercise or 75 to 150 min of vigorous-intensity exercise or
an equivalent combination. Guidance for strength training
is to perform at least two weekly sessions that include ex-
ercises for major muscle groups [14].
Implementation of exercise training
Exercise programmes of supervised training achieves high-
er fitness levels than unsupervised training [15]. Exercise
training has to be personalised, based on cancer stage,
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patients’ preferences and abilities [11]. Before treatment,
during treatment (phase I) and early after treatment (phase
II) it can be integrated in comprehensive cancer rehabilita-
tion programmes. Programmes should implement concepts
for long-term adherence (phase III) to individual exercise
training, both for cancer survivors and in palliative situa-
tions [9]. The “National Cancer Strategy 2014-2017” high-
lighted the importance of cancer rehabilitation [16]. How-
ever, in Switzerland, cancer rehabilitation is currently not
covered by the compulsory health insurance, unlike car-
diac rehabilitation. Initiatives from https://oncoreha.ch and
the Swiss Cancer League are on the way. In clinical prac-
tice, ambulatory 3-month exercise training programmes
are most often reimbursed, when clinical necessity is ex-
plained. Several rehabilitation clinics offer inpatient cancer
rehabilitation. A study from the University Hospital of
Zurich showed that 42% of cancer patients participated in
inpatient rehabilitation programmes. Longer hospital stay,
unemployment, supplementary health insurance and
woman with advanced tumour stages were associated with
programme uptake [17].
Cancer rehabilitation programmes may benefit from
lessons learned in cardiac rehabilitation. Based on the EU-
ROASPIRE IV and V surveys that have been conducted
in 78 centres from 25 European countries, only half of
all coronary artery disease patients were referred to and
only 40% attended a cardiac rehabilitation program [18].
In heart failure patients, who have some similarities to
cancer patients, such as exercise intolerance, referral and
uptake are even lower [19]. This illustrates the unused
potential for improving quality of life and outcomes for
patients. Some barriers for implementation may be similar
for cardiac and cancer patients. Healthcare professionals
may doubt the value of exercise, and there may be a lack
of available regional rehabilitation programmes and/or ed-
ucated personnel. On a patient level, adherence to exercise
may be low owing to socioeconomic factors, disease sever-
ity, co-morbidities, motivation, and personal beliefs and
expectations [20]. Addressing these issues may contribute
to a more holistic approach to cancer treatment, making
exercise an important adjuvant therapy. There is an oppor-
tunity to use synergies between oncology and phase II /
phase III cardiac rehabilitation. Cancer patients could be
integrated in existing phase II cardiac rehabilitation pro-
grammes, based on their fitness level. Selected cancer pa-
tients may want to continue exercise during phase III in
supervised programmes and may participate in one of the
many regional heart groups in Switzerland (www.swiss-
heartgroups.ch).
Safety of exercise in cancer patients
In general, exercise is safe and feasible throughout the
cancer care pathway. Before beginning to exercise, a can-
cer-specific medical assessment is recommended. Exercise
testing should be performed before moderate to vigorous
exercises or sports. Relative and absolute contraindications
may vary between cancer types and have to be respected
(table 3) [21].
Table 3: Summary of the relative and absolute contraindications to
some or all types of exercise and sport in cancer patients (modified
from [13, 21]).
Relative contraindications Recent weight gain (>2 kg during
the 3 days preceding exercise)
Decrease in systolic blood pres-
sure during exercise
New York Heart Association class
IV cardiac status
Ventricular arrhythmia at rest or
during exercise
Supine heart rate ≥100 beats/min
Neurological toxicity >grade 2
Asymptomatic central neurologi-
cal lesions
Asymptomatic bone metastases
Absolute contraindications Progressive increase in dyspnoea
at rest or during exercise for the
3–5 days preceding exercise
Uncontrolled diabetes mellitus
Acute disease or fever
Recent embolism
Thrombophlebitis
Myocarditis or active pericarditis
Symptomatic central neurological
lesions
Haematological toxicity: platelets
<50 000/mm3, leucocytes <1500/
mm3, haemoglobin <8 g/dl
Symptomatic central neurological
lesions
Osteolytic or painful bone metas-
tases
Gaps in evidence
Multiple research gaps remain in this field, including the
need for greater specificity about the dose-response effects
of specific modes of exercise training on specific endpoints
and within a broader range of cancer populations, and data
on participation of cancer patients in competitive sports
[13].
Key points
– Cancer and cardiovascular diseases share modifiable
risk factors.
– Adjuvant radio- and/or chemotherapies increase cardio-
vascular risk in cancer survivors.
– Exercise intolerance in cancer patients is multifactorial
and contributes to their elevated cardiovascular risk.
– Exercise is safe and feasible throughout the cancer care
pathway and positively affects physical function, body
composition, quality of life and possibly prognosis in
selected cancers. Cancer-specific contraindications
have to be respected.
– Exercise training should be personalised and can be in-
tegrated into comprehensive cancer rehabilitation pro-
grammes.
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